FdaApplication
NDA 020823
Identifiers
- fda_app_no: NDA020823
Properties
| Property | Value |
|---|---|
| applicant_name | NOVARTIS PHARMACEUTICALS CORP |
| application_type | NDA |
| approval_date | 2000-04-21 |
Products (4)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| EXELON | RIVASTIGMINE TARTRATE | EQ 3MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | CAPSULE;ORAL |
| EXELON | RIVASTIGMINE TARTRATE | EQ 1.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | CAPSULE;ORAL |
| EXELON | RIVASTIGMINE TARTRATE | EQ 4.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | CAPSULE;ORAL |
| EXELON | RIVASTIGMINE TARTRATE | EQ 6MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | CAPSULE;ORAL |
4 products